Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%)...
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3...
RIVERVIEW, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- River Oaks Treatment Center is proud to announce that it has two additional board-certified addiction medicine physicians on its staff. Dr....
Ark Clinical Research Announces Advancing Accessibility for Obesity Through Innovative Research Trials on GLP-1 drugs
T-cell therapy developer, Cbio A/S cecures DKK40M in Financing to enter clinical stage in cervical cancer
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT„¢ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior...
Preclinical study demonstrates potential of Autonomix technology to make renal denervation safer and more effective Ongoing advancement of sensing and ablation technologies toward proof-of-concept...
RESEARCH TRIANGLE PARK, N.C. and OSAKA, Japan, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite, and Linical Americas, a U.S. subsidiary of The Linical Group, a leading global contract research organization (CRO), today announced a partnership that will facilitate the deployment of decentralized clinical trial solutions—powered by Science 37—to Linical’s international clients, enabling patient access from virtually anywhere.